This Analyst Believes Precigen's Non-Healthcare Divesture Removes Financial Overhang

  • Yesterday, Precigen Inc PGEN agreed to sell its non-healthcare subsidiary to URUS.
  • HC Wainwright says they are encouraged by the divestiture of the company's non-core business and believe management deserves much credit, especially against the backdrop of the challenging macro environment. 
  • Related: Why Precigen Shares Are Gaining Today?
  • The analyst believes the completed transaction would remove the financial overhang related to the approximate $200 million convertible notes that mature in July 2023. 
  • The company ended the March quarter with cash and equivalents of $142.1 million.
  • "We believe this transaction not only strengthens Precigen's balance sheet by providing a substantial amount of non-dilutive cash but also helps focus the company's resources on developing its clinical assets," the analyst added.
  • The Trans Ova divestiture could potentially drive more investors' attention onto Precigen's healthcare-focused portfolio, says HC Wainwright.
  • The firm maintains its Buy rating on PGEN with a price target of $10 per share.
  • Price Action: PGEN shares are down 9.20% at $1.47 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechM&ANewsPenny StocksHealth CarePrice TargetReiterationSmall CapAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!